This content is machine translated Anti-dementia drugs Insight into everyday care in Switzerland The proportion of anti-dementia drugs used varies according to age. While ginkgo biloba predominates up to the age of 70, cholinesterase inhibitors and memantine are used comparatively more from the…
View Post 4 min This content is machine translated MCI and dementia Ginkgo biloba extract as an add-on scores well in cohort study The results of a retrospective cohort study with data from over 500 patients indicate that the use of a proprietary Ginkgo biloba extract in combination with an acetylcholinesterase inhibitor and/or…
View Post 3 min This content is machine translated Mild cognitive impairment (MCI) Ginkgo biloba extract promotes dual-task gait safety Many older people with MCI have reduced gait stability. It has been shown that improved dual tasking during walking significantly reduces the risk of falling. An exploratory study was conducted…
View Post 5 min This content is machine translated Mild cognitive impairment (MCI): neuroprotective factors Flavonoids have an antioxidant effect For many people with MCI, cognitive abilities remain stable or improve again, while others develop dementia over time. In the context of lifestyle research, there are many findings on diet-related…
View Post 4 min This content is machine translated "Mild Cognitive Impairment" (MCI). Ginkgo biloba for the improvement of neurocognitive symptoms Patients with mild cognitive function impairment – mostly affecting those over 60 years of age – may benefit from symptomatic therapy based on a standardized extract of ginkgo. This is…
View Post 6 min This content is machine translated "Mild Cognitive Impairment" Halting progression to dementia with herbal extracts Stopping the progression to manifest dementia is one of the overarching therapeutic goals in the treatment of mild cognitive impairment (MCI). A randomized placebo-controlled trial investigated related effects of two…
View Post 5 min This content is machine translated "Mild Cognitive Impairment" (MCI). How can progression be delayed? Patients with “Mild Cognitive Impairment” (MCI) have an increased risk of developing manifest dementia. The evidence on drug treatments that slow the progression of neurocognitive impairment is mixed. In terms of…
View Post 4 min This content is machine translated Alzheimer Congress in Toronto Neuropsychiatric symptoms as precursors of dementia In July, the Alzheimer’s Association held its first international congress (AAIC 2016). More than 5000 experts and researchers from 70 countries gathered in Toronto to share news and study results…
View Post 6 min This content is machine translated 4th Basel Dementia Forum A lot has happened In Basel, an update on diagnostics and therapy was given at this year’s Dementia Forum. The two experts Prof. Dr. phil. Andreas U. Monsch and Prof. Dr. med. Reto W.…
